2017
DOI: 10.1038/s41598-017-14020-9
|View full text |Cite
|
Sign up to set email alerts
|

A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort

Abstract: Alzheimer’s Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer’s parti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(20 citation statements)
references
References 82 publications
0
20
0
Order By: Relevance
“…However, the collected plasma and DNA samples may be suitable for other AD blood biomarker candidates of interest, including a variety of protein, lipid, and microRNA species, as well as mitochondrial genes or DNA epigenetic modification patterns [25][26][27][28][29][30][31][32]. They may be evaluated in future studies carried out in PharmaCog/E-ADNI "positive" and "negative" aMCI groups.…”
Section: Discussionmentioning
confidence: 99%
“…However, the collected plasma and DNA samples may be suitable for other AD blood biomarker candidates of interest, including a variety of protein, lipid, and microRNA species, as well as mitochondrial genes or DNA epigenetic modification patterns [25][26][27][28][29][30][31][32]. They may be evaluated in future studies carried out in PharmaCog/E-ADNI "positive" and "negative" aMCI groups.…”
Section: Discussionmentioning
confidence: 99%
“…In the advent of large well characterized research cohorts that now include Aβ PET and/or CSF Aβ measures as routine, the opportunity to use an "endophenotype" approach to discover peripheral markers of Aβ pathology is ever increasing. Pilot data suggest associations of the concentrations of a number of plasma proteins (e.g., pancreatic polypeptide Y, IgM, chemokine ligand 13, interleukin 17, vascular cell adhesion protein 1, 2-macroglobulin, apolipoprotein A1, fibrinogen gamma chain, interleukins and complement proteins) and metabolites with Aβ burden in the brain [128][129][130][131][132][133][134]. However, these data should be interpreted with some caution, as they are derived from multi-marker panels and as a mechanistic understanding of the associations is currently lacking.…”
Section: Blood-based Biomarkers For Aβ Pathologymentioning
confidence: 99%
“…IL‐12 is a similarly important PRO‐inflammatory protein, and antagonizes many of IL‐10's effects. Both are associated with amyloid deposition in the Australian Imaging, Biomarker & Lifestyle Flagship Study on Ageing (ABIL) [43]. IL‐12 is also unavailable in the ADNI, but loads significantly on INFLAMMATION in the TARCC, and inversely to IL‐10 (data not shown).…”
Section: Discussionmentioning
confidence: 99%